BioStem Technologies (BSEM)
OTHER OTC:BSEM
Top Page
BioStem Technologies
(OTC:BSEM)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.00
▲(3.52% Upside)
Action:ReiteratedDate:04/09/26
The score is primarily constrained by volatile financial performance (sharp 2025 revenue/earnings deterioration) and earnings-call-flagged near-term liquidity and execution risks amid a steep 2026 revenue guide. Technicals are neutral-to-weak with negative MACD and price below longer-term averages, while valuation is also pressured by losses and no dividend support; strategic acquisition and clinical/margin-upside catalysts partially offset these risks.
Positive Factors
Strategic Acquisition & Commercial Expansion
The BioTissue acquisition immediately expands BioStem into hospital, HOPD and ASC channels and brings an experienced national sales footprint. Adding ~ $29M of historical revenue and re-assigned GPO contracts diversifies payer/customer mix and structurally broadens addressable markets for durable revenue sources.
Negative Factors
Revenue Volatility & Sharp Decline
Revenue fell sharply year-over-year and 2025 showed a severe annual contraction, which undermines visibility and earnings quality. Such volatility strains planning for commercialization and manufacturing investments, increases refinancing/dilution risk, and makes multi-quarter margin recovery and cashflow forecasting more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Acquisition & Commercial Expansion
The BioTissue acquisition immediately expands BioStem into hospital, HOPD and ASC channels and brings an experienced national sales footprint. Adding ~ $29M of historical revenue and re-assigned GPO contracts diversifies payer/customer mix and structurally broadens addressable markets for durable revenue sources.
Read all positive factors
BioStem Technologies (BSEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$83.82M
Dividend YieldN/A
Average Volume (3M)59.14K
Price to Earnings (P/E)―
Beta (1Y)1.95
Revenue Growth11.78%
EPS Growth37.44%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding16,338,436
10 Day Avg. Volume75,970
30 Day Avg. Volume59,143
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.63
Price to Sales (P/S)1.34
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.29
Enterprise Value/Gross Profit1.39
Enterprise Value/Ebitda-130.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.29
Revenue Forecast (FY)$271.30M
BioStem Technologies Business Overview & Revenue Model
Company Description
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a trea...
BioStem Technologies Earnings Call Summary
Earnings Call Date:Mar 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
Balanced: the call communicated meaningful strategic positives — a transformational acquisition expanding addressable markets, strong clinical data (DFU RCT), product and commercial expansion, and a clear path to materially higher manufacturing margins after tech transfer. However, these longer-term strengths are offset by significant near-term financial headwinds: steep year-over-year revenue declines, a sizable one-time $8.8M allowance tied to distributor collections, higher operating expenses, lower blended margins during a 12-month contract manufacturing period, reduced post-close cash (~$16M) and expected cash consumption through much of 2026. Management has articulated a credible integration and commercialization plan, but near-term liquidity and execution risks temper the outlook.Positive Updates
Strategic Acquisition of BioTissue Assets
Closed acquisition of BioTissue surgical and wound assets (closed Jan 21, 2026) that expands BioStem into hospital inpatient, HOPD and ASC settings, diversifies payer mix and adds ~ $29M of 2025 revenue from the acquired assets (per management).
Negative Updates
Sharp Year-over-Year Revenue Decline
Q4 2025 revenue of $10.1M vs $22.7M in Q4 2024, a decline of ~55.5% year-over-year; Q4 vs prior period ($10.5M) down ~3.8% sequentially.
Read all updates
Q4-2025 Updates
Positive
Negative
Strategic Acquisition of BioTissue Assets
Closed acquisition of BioTissue surgical and wound assets (closed Jan 21, 2026) that expands BioStem into hospital inpatient, HOPD and ASC settings, diversifies payer mix and adds ~ $29M of 2025 revenue from the acquired assets (per management).
Read all positive updates
Company Guidance
The company guided that after a Q4 2025 finish with $10.1M revenue and a 97% gross margin (Q4 ’24: $22.7M revenue, 84% margin), Q1 2026 revenue is expected to be $5.0–$6.0M as physician-office volumes decline markedly in early 2026 and the hospital business (the acquired BioTissue surgical assets generated ~$29M in 2025) performs in line with historical levels; BioStem expects the physician-office market to stabilize in H2 2026 and the hospital business to become the majority of 2026 revenue. Balance-sheet and integration metrics: cash was $29.5M at 12/31/25 (≈$16M post-close on 1/21/26), runway is forecast into late Q3 2026 excluding a $10M 510(k) milestone payment expected in H2 2026, and the acquisition structure includes a $15M upfront amount plus up to $15M in contingent royalties. Commercial and operational targets include integrating >25 direct reps and >30 independent agents (ramping to at least 40 direct reps), a 12‑month manufacturing supply agreement during which acquired-product gross margins are ~60% (including a 23% cost‑plus markup), and a targeted expansion back toward >80% gross margins after tech transfer; clinical and corporate milestones include published DFU top-line superiority, VLU top‑line results expected mid‑2026, completion of 2024/2025 KPMG audits near term, and pursuit of expanded payer coverage across a roughly $23B combined addressable market.BioStem Technologies Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
70
Positive
Cash Flow
61
Positive
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 47.48M | 301.83M | 16.69M | 6.88M | 4.34M |
| Gross Profit | 44.22M | 287.86M | 15.42M | 5.99M | 2.87M |
| EBITDA | -469.73K | 31.49M | -7.55M | -6.52M | -602.00K |
| Net Income | -6.58M | 31.88M | -8.48M | -7.07M | -1.45M |
Balance Sheet | |||||
| Total Assets | 50.03M | 140.55M | 14.56M | 3.47M | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 29.55M | 22.83M | 239.41K | 772.14K | 340.33K |
| Total Debt | 3.33M | 4.50M | 4.77M | 5.21M | 4.83M |
| Total Liabilities | 10.89M | 99.67M | 15.90M | 7.42M | 8.47M |
| Stockholders Equity | 39.14M | 40.88M | -1.34M | -4.08M | -5.96M |
Cash Flow | |||||
| Free Cash Flow | 6.59M | 24.05M | -3.60M | -2.11M | -152.29K |
| Operating Cash Flow | 9.94M | 24.48M | -3.50M | -1.64M | -109.44K |
| Investing Cash Flow | -2.10M | -1.68M | -210.33K | -469.48K | -7.85K |
| Financing Cash Flow | -1.12M | -206.78K | 3.18M | 597.71K | 357.42K |
BioStem Technologies Technical Analysis
Positive
4.83
Price Trends
5.57
Negative
4.96
Positive
6.31
Negative
Market Momentum
-0.14
Negative
51.06
Neutral
63.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSEM, the sentiment is Positive. The current price of 4.83 is below the 20-day moving average (MA) of 4.94, below the 50-day MA of 5.57, and below the 200-day MA of 6.31, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 51.06 is Neutral, neither overbought nor oversold. The STOCH value of 63.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BSEM.
BioStem Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $333.53M | ― | -77.62% | ― | ― | -29.73% | |
52 Neutral | $83.82M | -9.69 | -14.25% | ― | 11.78% | 37.44% | |
52 Neutral | $143.22M | 6.18 | 17.46% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $504.84M | -8.24 | -122.12% | ― | -100.00% | -0.58% | |
47 Neutral | $233.63M | -1.93 | -51.35% | ― | -80.88% | -388.61% | |
47 Neutral | $130.56M | -1.23 | -271.32% | ― | -75.77% | -31.24% |
* Healthcare Sector Average
BSEM
BioStem Technologies
5.20
-4.11
-44.15%
CBIO
Crescent Biopharma
19.10
-0.36
-1.85%
VYGR
Voyager Therapeutics
3.96
0.97
32.44%
DMAC
Diamedica Therapeutics
6.18
2.67
76.07%
BDTX
Black Diamond Therapeutics
2.58
1.16
81.69%
IPHA
Innate Pharma
1.45
-0.37
-20.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.